D-Tat57-49 (retro-inverso Tat)
Sequence: rrrqrrkkr
| Experiment Id | EXP000909 |
|---|---|
| Paper | Cell-Penetrating Peptides and Peptide Nucleic Acid-Coupled MRI Contrast Agents: Evaluation of Cellul |
| Peptide | D-Tat57-49 (retro-inverso Tat) |
| Delivery Success Class | no |
| In Vivo Flag | no |
| Uptake Confirmed | yes |
| Label Confidence | high |
| In Vitro Functional Effect | no |
| Endosomal Escape Evidence | no |
| Peptide Concentration | 2.5 µM (typical; tested up to 5 µM) |
| Rna Concentration | 2.5 µM (same as conjugate) |
| Mixing Ratio | |
| Formulation Format | covalent CPP–PNA–Gd(DOTA)–FITC conjugate |
| Formulation Components | CPP (D-Tat57-49) + AEEA spacer + PNA (12mer) + Lys(FITC) + Gd(DOTA) |
| Size Nm | |
| Zeta Mv | |
| Model Scope | in_vitro |
| Model Type | in vitro |
| Cell Lines Or Primary Cells | DsRed2-expressing CCL-11 fibrosarcoma (DsRed cells); CCL-11 parent |
| Animal Model | |
| Administration Route | |
| Output Type | uptake / imaging contrast |
| Output Value | Efficient uptake; significant MR contrast enhancement at low µM |
| Output Units | |
| Output Notes | Uptake confirmed by fluorescence spectroscopy/microscopy and MR imaging; conjugates localized to perinuclear vesicles with endosomal/lysosomal entrapment and little/no cytosolic release; no specific mRNA targeting observed in cells vs nonsense control. |
| Toxicity Notes | At >2.5 µM, dose increase increased toxicity with only marginal delivery benefit; 2.5 µM used for subsequent studies. |
| Curation Notes |